Consent given pursuant to Sections 14 and 14A to the supply of the therapeutic goods specified by Pfizer Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to provide a comprehensive framework for the regulation of therapeutic goods in Australia, addressing the need for a unified legislative approach to ensure the safety, quality, and efficacy of these products. The Act was introduced to fill a significant gap in the regulation of therapeutic goods, which previously lacked a cohesive legislative structure, potentially leading to inconsistencies and oversights in consumer protection and public health safety. Enacted by the Parliament of Australia, the Act aims to ensure that therapeutic goods available in the market are safe, of high quality, and that their benefits outweigh any potential risks, thereby protecting the health and wellbeing of the Australian population. The Therapeutic Goods Administration, operating under the auspices of the Department of Health, administers the Act, exercising powers to regulate the importation, supply, and advertising of therapeutic goods, among other responsibilities. The policy objective underlying the Act is to maintain and improve the health of the Australian public by regulating therapeutic goods effectively, thereby facilitating access to quality, safe, and efficacious therapeutic goods while mitigating potential health risks associated with their use.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods in Australia, encompassing a wide range of products including medicines, medical devices, blood, and tissues. This legislation applies to various entities such as manufacturers, importers, and suppliers of therapeutic goods, ensuring that these goods meet safety, quality, and efficacy standards before they are made available to the public. The Act's jurisdiction extends across the Commonwealth, with the Therapeutic Goods Administration (TGA) being the regulatory body responsible for enforcing the provisions of the Act. The Act can include exclusions and exemptions for certain goods, particularly those intended for research or personal use, and it also allows for the creation of subordinate instruments to further define and refine the application of the primary Act. These subordinate instruments can extend or restrict the application of the Act, providing more detailed guidelines and regulations to support the overarching legislative framework. In the specific case of the Therapeutic Goods Act 1989, a delegate of the Secretary of the Department of Health granted consent under sections 14 and 14A to Pfizer Australia Pty Ltd for the supply of certain batches of DONNATAB tablets that did not conform to the labelling requirements specified in Therapeutic Goods Order No. 69. This consent was effective for a limited period and applied only to the specified batches, illustrating the Act's capacity to provide targeted regulatory relief where necessary while maintaining overall public safety and product quality. The Act’s detailed and comprehensive scope ensures that therapeutic goods supplied in Australia meet rigorous standards, safeguarding the health and wellbeing of the population.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) provides mechanisms through which therapeutic goods can be supplied under certain conditions. In particular, sections 14 and 14A of the Act allow for consent to be given for the supply of therapeutic goods that do not fully comply with certain regulatory requirements, under specific conditions. This consent is conditional and time-limited. For instance, on 27 October 2015, a delegate of the Secretary of the Department of Health granted consent to Pfizer Australia Pty Ltd for the supply of specific batches of DONATAB tablets (sections 14 and 14A). This consent was granted because these particular batches of the medication did not include the specific advisory statements required by the Medicines Advisory Statements Specification 2014, as mandated by paragraph 3(2)(g) of Therapeutic Goods Order No. 69. The Act imposes several obligations on entities such as Pfizer Australia Pty Ltd that seek to supply therapeutic goods under these sections. Firstly, they must apply for consent from a delegate of the Secretary of the Department of Health, detailing the specific non-compliance and the reasons for it. The application must be made in good faith and with adequate justification. The delegate then reviews the application to determine whether granting consent would not be likely to cause unacceptable health or safety risks. If satisfied, the delegate may consent to the supply under certain conditions and for a specified period. Failure to adhere to the conditions set out in the consent, or supplying the goods outside of the specified period, may result in legal consequences. Under the Act, supplying goods without the required consent, or contravening the conditions of consent, can constitute an offence. The penalties for contravening the Act can be severe, including fines and imprisonment. Specifically, for corporations, the maximum penalty can be substantial, reflecting the seriousness of supplying goods that may pose health or safety risks. Individuals responsible for the contravention may also face personal penalties, which can include fines and imprisonment terms as stipulated by the relevant provisions of the Act.